AVALO THERAPEUTICS, INC. Accrued Marketing Costs, Current
AVALO THERAPEUTICS, INC. (AVTX) had Accrued Marketing Costs, Current of $92.00 thousand as of 2022-03-31, per its 10-Q filed 2022-05-05.
Discontinued › Notes › Payables and Accruals
us-gaap:AccruedMarketingCostsCurrent · last filed 2022-05-05
- 2022-03-31: Accrued Marketing Costs, Current $92.00K.
- 2021-12-31: Accrued Marketing Costs, Current $111.00K.
- 2021-09-30: Accrued Marketing Costs, Current $360.00K.
- 2021-06-30: Accrued Marketing Costs, Current $246.00K.
| Period end | Accrued Marketing Costs, Current | Accrued Marketing Costs, Current as first filed |
|---|---|---|
| 2022-03-31 | $92.00K 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $111.00K 10-Q · filed 2022-05-05 | |
| 2021-09-30 | $360.00K 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $246.00K 10-Q · filed 2021-08-02 | |
| 2021-03-31 | $93.00K 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $31.00K 10-K · filed 2022-03-02 | $30.80K 10-K · filed 2021-03-08 |
| 2020-09-30 | $142.00K 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $212.81K 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $207.95K 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $120.06K 10-K · filed 2021-03-08 | |
| 2019-09-30 | $125.49K 10-Q · filed 2019-11-14 | |
| 2019-06-30 | $627.02K 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $938.44K 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $235.72K 10-K · filed 2020-03-11 | |
| 2017-12-31 | $0.00 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |